Alzheimer's Research & Therapy | Most Viewed

Submit a manuscript Register Follow us on

Explore journal

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
	1. 889 Accesses	Review Examining the mechanisms that link β-amyloid and α-synuclein pathologies Samuel E Marsh, Mathew Blurton-Jones Alzheimer's Research & Therapy 2012, 4:11 (30 April 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Marsh and Blurton-Jones review evidence suggesting β-amyloid (Aβ) and α-synuclein (α-syn) interact synergistically to enhance aggregation and accelerate cognitive decline, and propose potential mechanistic links between Aβ and α-syn pathologies.
	2. 607 Accesses	Commentary Long-term benefit from deep brain stimulation of the subthalamic nucleus: is it for everyone? Jerrold L Vitek Alzheimer's Research & Therapy 2012, 4:13 (9 May 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Jerrold Vitek comments on a recent research article addressing how long the benefits of deep brain stimulation for the treatment of Parkinson's disease (PD) can be sustained.
	3. 603 Accesses	Review Dementia prevention: current epidemiological evidence and future perspective Francesca Mangialasche, Miia Kivipelto, Alina Solomon, Laura Fratiglioni Alzheimer's Research & Therapy 2012, 4:6 (13 February 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Mangialasche and colleagues address current epidemiological research and intervention studies to identify promising preventative strategies for Alzheimer's disease (AD) and dementia; considering the need for randomized controlled trials to confirm these findings.
	4. 584 Accesses	Review Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems Sally Hunter, Carol Brayne Alzheimer's Research & Therapy 2012, 4:10 (13 April 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Hunter and Brayne build a map, modelling relationships between the amyloid precursor protein (APP) and its proteolytic fragments with other neuronal systems and discussing alternative perspectives for its role in Alzheimer's disease progression.
	5. 484 Accesses	Review Cognitive reserve, cortical plasticity and resistance to Alzheimer's disease Margaret M Esiri, Steven A Chance Alzheimer's Research & Therapy 2012, 4:7 (1 March 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Esiri and Chance discuss the impact of epidemiological factors on cognitive reserve and cortical plasticity, which act as preventative factors against cognitive decline and the development of Alzheimer's disease (AD) in the elderly.
	6. 472 Accesses	Research Reduction of low-density lipoprotein receptor-related protein (LRP1) in hippocampal neurons does not proportionately reduce, or otherwise alter, amyloid deposition in APPswe/PS1dE9 transgenic mice Guilian Xu, Cameron C Green, Susan E Fromholt, David R Borchelt Alzheimer's Research & Therapy 2012, 4:12 (26 April 2012) Abstract \| Provisional PDF \| PubMed \| Editor’s summary Reduction in levels of low-density lipoprotein receptor-related protein (LRP1) in an in vivo mouse model failed to observe a reduction in amyloidosis, questioning its significance as a potential therapeutic target for Alzheimer's disease.
	7. 450 Accesses	Research Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010) Abstract \| Full text \| PDF \| PubMed
	8. 384 Accesses	Review Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease Sascha Weggen, Dirk Beher Alzheimer's Research & Therapy 2012, 4:9 (30 March 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The molecular consequences of amyloid precursor protein and presenilin gene mutations in familial Alzheimer's disease (FAD) are examined by Weggen and Beher; in view of potential therapeutic treatments directed at amyloid-beta peptides.
	9. 339 Accesses	Research Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
	10. 269 Accesses	Commentary Resting-state fMRI as a biomarker for Alzheimer's disease? Jessica S Damoiseaux Alzheimer's Research & Therapy 2012, 4:8 (15 March 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Damoiseaux comments on a recent review discussing resting-state functional magnetic resonance imaging (fMRI) in the study of Alzheimer's disease, considering key aspects surrounding its biomarker potential.
	11. 259 Accesses	Review Lipidomics of Alzheimer's disease: current status Paul L Wood Alzheimer's Research & Therapy 2012, 4:5 (1 February 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Current applications of lipidomic technologies and the potential roles of lipid deficits and alterations in the pathophysiology of Alzheimer's disease (AD) are discussed by Wood.
	12. 259 Accesses	Research Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui, Jacek J Jagodzinski, Pamela S Keim, Dora Kholodenko, Lee H Latimer, Mike Lee, Jennifer Marugg, Matthew N Mattson, Scott McCauley, James L Miller, Ruth Motter, Linda Mutter, Martin L Neitzel, Huifang Ni, Lan Nguyen et al. Alzheimer's Research & Therapy 2010, 2:36 (29 December 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary An amyloid precursor protein selective gamma-secretase inhibitor demonstrates selectivity for inhibiting Amyloid beta production in Alzheimer’s disease transgenic mice and needs to be corroborated in wild-type mice.
	13. 246 Accesses	Review Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND) Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil, Carol Brayne Alzheimers Res Ther 2009, 1:4 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stephan et al. review the concept of ‘vascular cognitive impairment, no dementia’ (VCIND) and its application for screening individuals at increased risk of dementia secondary to vascular disease and its risk factors.
	14. 244 Accesses	Review Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes, Delphine Boche Alzheimers Res Ther 2010, 2:1 (22 January 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Zotova et al. review the immune processes involved in Alzheimer’s disease pathogenesis and highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies.
	15. 241 Accesses	Research Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun, Yikang Xu Alzheimer's Research & Therapy 2011, 3:22 (20 June 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Increasing the dose of donepezil to 23 mg/d may provide language benefits in patients with moderate to severe Alzheimer’s disease (AD), for whom preservation of language abilities is especially critical.
	16. 239 Accesses	Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
	17. 230 Accesses	Review The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Kerensa Broersen, Frederic Rousseau, Joost Schymkowitz Alzheimer's Research & Therapy 2010, 2:12 (14 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta has been identified as neurotoxic in patients with Alzheimer’s disease (AD), but we must take into account its structural characteristics, as well as size, when exploring AD development.
	18. 207 Accesses	Research Predictors of long-term cognitive outcome in Alzheimer's disease Carina Wattmo, Åsa K Wallin, Elisabet Londos, Lennart Minthon Alzheimer's Research & Therapy 2011, 3:23 (20 July 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Clinical predictors of a more favorable longitudinal outcome in Alzheimer's disease include male gender, older age, absence of the apolipoprotein E e4 allele, treatment with non-steroidal anti-inflammatory drugs or a higher mean dose of cholinesterase inhibitor.
	19. 191 Accesses	Review Genetics of Alzheimer disease in the pre- and post-GWAS era Nilüfer Ertekin-Taner Alzheimer's Research & Therapy 2010, 2:3 (5 March 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Ertekin-Taner summarises genetic studies preceding the genome-wide association study (GWAS) era and discusses insights into genetics of Alzheimer’s following recent GWAS results, which may translate into future therapies.
	20. 189 Accesses	Review PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease Michael J Pontecorvo, Mark A Mintun Alzheimer's Research & Therapy 2011, 3:11 (29 March 2011) Abstract \| Full text \| PDF \| PubMed
	21. 188 Accesses	Research Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine Alzheimer's Research & Therapy 2011, 3:16 (19 April 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The selective oral tyrosine kinase inhibitor, masitinib, administered as an adjunctive therapy, slows the rate of cognitive decline in Alzheimer’s disease (AD) although further studies are needed to investigate its efficacy and safety.
	22. 185 Accesses	Research A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease Sebastian Palmqvist, Lennart Minthon, Carina Wattmo, Elisabet Londos, Oskar Hansson Alzheimer's Research & Therapy 2010, 2:29 (15 October 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A Quick Test of cognitive speed is twice as sensitive as the mini-mental state examination in evaluating cholinesterase inhibitor treatment in Alzheimer’s disease patients, indicating its potential usefulness in the primary care setting.
	23. 183 Accesses	Research CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo, Pekka J Karhunen Alzheimer's Research & Therapy 2011, 3:12 (5 April 2011) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary CLU, CR1 and PICALM genes are not strongly related to senile plaque prevalence, or at all to neurofibrillary tangles, and most likely do not affect the development of these Alzheimer’s disease (AD) lesions.
	24. 181 Accesses	Research Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice Vjera A Holthoff, Steven Ferris, Ralf Ihl, Philippe Robert, Bengt Winblad, Serge Gauthier, Kati Sternberg, Frank Tennigkeit Alzheimer's Research & Therapy 2011, 3:27 (14 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The Relevant Outcome Scale for Alzheimer's disease (ROSA) is a valid and reliable instrument to aid medical practitioners in the routine assessment of the severity of Alzheimer's disease symptoms and disease progression.
	25. 166 Accesses	Commentary Herbal therapy: a new pathway for the treatment of Alzheimer's disease Jinzhou Tian, Jing Shi, Xuekai Zhang, Yongyan Wang Alzheimer's Research & Therapy 2010, 2:30 (22 October 2010) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary On the basis of current evidence, Tian and colleagues discuss whether herbal therapy could be a novel pathway to treat Alzheimer’s disease (AD) and the implications of these results on future therapy development.